StreetInsider.com News Articles

ENLIVEX TO PRESENT QUALITY LONGEVITY MODEL POWERED BY PREDICTION MARKETS TREASURY AT PROOF OF TALK 2026

Tue, 02 Jun 2026 08:00:00 -0400

As a Gold Sponsor of the Paris event, Enlivex will host a curated dinner today for leading institutional asset managers, allocators, and digital asset investors

Nes-Ziona, Israel, June 02, 2026 (GLOBE NEWSWIRE) -- Enlivex Ltd. (Nasdaq: ENLV, "Enlivex" or the "Company"), a quality longevity company powered by a prediction markets treasury, today announced that it is a Gold Sponsor of Proof of Talk 2026, taking place June 2-3, 2026, at the Louvre Palace and Musée des Arts Décoratifs in Paris. Proof of Talk is one of Europe's leading institutional summits on digital assets, convening approximately 2,500

ENLIVEX TO PRESENT QUALITY LONGEVITY MODEL POWERED BY PREDICTION MARKETS TREASURY AT PROOF OF TALK 2026

Tue, 02 Jun 2026 08:00:00 -0400

As a Gold Sponsor of the Paris event, Enlivex will host a curated dinner today for leading institutional asset managers, allocators, and digital asset investors

Enlivex to present Allocetra knee osteoarthritis data at EULAR congress

Mon, 01 Jun 2026 08:00:58 -0400

Enlivex Ltd. (NASDAQ: ENLV) announced it will present clinical data from its Phase IIa trial of Allocetra at the European Alliance of Associations for Rheumatology congress in London from June 3-7, 2026.

The presentation will feature 6-month clinical data from the Phase IIa trial (NCT06233474) of Allocetra in patients with moderate-to-severe knee osteoarthritis. According to the company, the results showed statistically significant improvement compared to placebo in pain reduction and functional improvement in patients aged 60 years and older.

Prof. Philip Conaghan, Consultant Rheumatologist and Director of the NIHR Leeds Biomedical Research Centre, will deliver the oral presentation on June 3, 2026,

Allocetra Shows Durable 6-Month Efficacy in Knee Osteoarthritis Phase IIa Trial; Oral Presentation at EULAR 2026

Mon, 01 Jun 2026 08:00:00 -0400

The data were selected for an oral podium presentation at EULAR and will be presented by Prof. Philip Conaghan, a globally recognized key opinion leader in osteoarthritis

Nes-Ziona, Israel, June 01, 2026 (GLOBE NEWSWIRE) -- Enlivex Ltd. (Nasdaq: ENLV, "Enlivex" or the "Company"), a quality longevity company powered by a prediction markets treasury, today announced that it will present at the European Alliance of Associations for Rheumatology (EULAR) European Congress of Rheumatology, taking place June 3-7, 2026, in London, UK.

The presentation will feature extended 3-month and 6-months clinical data, as well as comprehensive

Allocetra Shows Durable 6-Month Efficacy in Knee Osteoarthritis Phase IIa Trial; Oral Presentation at EULAR 2026

Mon, 01 Jun 2026 08:00:00 -0400

The data were selected for an oral podium presentation at EULAR and will be presented by Prof. Philip Conaghan, a globally recognized key opinion leader in osteoarthritis

The presentation will feature extended 3-month and 6-months clinical data, as well as comprehensive

Form 6-K Enlivex Ltd. For: May 28

Thu, 28 May 2026 08:05:00 -0400

si-local-file:///var/storage/secattach/20260528/26561513.html

Form 6-K Enlivex Ltd. For: May 28

Thu, 28 May 2026 08:05:00 -0400

si-local-file:///var/storage/secattach/20260528/26561513.html

Enlivex reports $1.16 billion RAIN token holdings as of May 27

Thu, 28 May 2026 08:01:00 -0400

Enlivex Ltd. (NASDAQ: ENLV) announced that its RAIN token holdings were valued at approximately $1.16 billion as of May 27, 2026. The company held 79,568,550,005 RAIN tokens as part of its prediction markets treasury strategy.

The Rain Foundation, which oversees the Rain protocol, appointed five industry leaders to its advisory board. The appointees include Stefan Rust, former CEO of Bitcoin.com; Dennis Liu, a crypto analyst known as Virtual Bacon; Route2FI, a financial writer and crypto influencer; David Airey, COO of Crypto Banter; and Danny Frishman, a technology entrepreneur with blockchain experience.

According to the Rain Foundation, the Rain protocol achieved more than

Enlivex reports $1.16 billion RAIN token holdings value

Thu, 28 May 2026 08:00:57 -0400

Enlivex Ltd. (NASDAQ: ENLV) reported holding 79,568,550,005 RAIN tokens valued at approximately $1.16 billion as of May 27, 2026, according to a company statement.

The Rain Foundation, which oversees the Rain protocol, appointed five industry figures to its advisory board. The appointees include Stefan Rust, former CEO of Bitcoin.com; Dennis Liu, a crypto analyst; Route2FI, a financial writer; David Airey, COO of Crypto Banter; and Danny Frishman, a technology entrepreneur.

The Rain protocol reported more than 29,000 users and over 100 million RAIN tokens burned through its buyback mechanism as of April 27, 2026. The Rain Foundation announced a $100 million liquidity

Enlivex Treasury Portfolio Update: RAIN Holdings Valued at Approximately $1.16 Billion; Rain Foundation Appoints Industry Leaders to Advisory Board

Thu, 28 May 2026 08:00:00 -0400

As of May 27, 2026, Enlivex held 79,568,550,005 RAIN tokens with a total value of approximately $1.16 billion.
Separately, the Rain Foundation recently announced the appointment of five industry leaders to its advisory board, supporting the next phase of growth of the Rain protocol, the primary digital asset in Enlivex's prediction markets treasury strategy.

Nes-Ziona, Israel, May 28, 2026 (GLOBE NEWSWIRE) -- Enlivex Ltd. (Nasdaq: ENLV, "Enlivex" or the “Company"), a quality longevity company powered by a prediction markets treasury, today provided an update on its RAIN token holdings. As of May 27,

Enlivex Treasury Portfolio Update: RAIN Holdings Valued at Approximately $1.16 Billion; Rain Foundation Appoints Industry Leaders to Advisory Board

Thu, 28 May 2026 08:00:00 -0400

As of May 27, 2026, Enlivex held 79,568,550,005 RAIN tokens with a total value of approximately $1.16 billion.
Separately, the Rain Foundation recently announced the appointment of five industry leaders to its advisory board, supporting the next phase of growth of the Rain protocol, the primary digital asset in Enlivex's prediction markets treasury strategy.

Form 6-K Enlivex Ltd. For: May 27

Wed, 27 May 2026 08:05:00 -0400

si-local-file:///var/storage/secattach/20260527/26553907.html

Form 6-K Enlivex Ltd. For: May 27

Wed, 27 May 2026 08:05:00 -0400

si-local-file:///var/storage/secattach/20260527/26553907.html

Enlivex Treasury Portfolio Update: Rain Protocol Jumps Into Top Three Global Prediction Markets In League Table Following $100M In Additional Liquidity

Wed, 27 May 2026 08:00:00 -0400

Rain, with an additional $100 Million Liquidity Commitment, Currently Anchors Top Three Positioning Among Global Prediction Market Leaders, Following Polymarket, with Approximately $450 million, and Kalshi1.
Rain’s Upgraded Positioning as a Top-3 Prediction Market and the Scale of its Capital Deployment Reinforce the Potential of the Enlivex Treasury Strategy
As of May 26, 2026, Enlivex's RAIN token holdings were 79,568,550,005 tokens, with a total value of approximately $919 million.
In addition, Enlivex holds an option to acquire up to 271,372,418,179 RAIN tokens from the Rain Foundation, at a purchase price of $0.0033 per RAIN token. The option’s

Enlivex Treasury Portfolio Update: Rain Protocol Jumps Into Top Three Global Prediction Markets In League Table Following $100M In Additional Liquidity

Wed, 27 May 2026 08:00:00 -0400

Rain, with an additional $100 Million Liquidity Commitment, Currently Anchors Top Three Positioning Among Global Prediction Market Leaders, Following Polymarket, with Approximately $450 million, and Kalshi1.
Rain’s Upgraded Positioning as a Top-3 Prediction Market and the Scale of its Capital Deployment Reinforce the Potential of the Enlivex Treasury Strategy
As of May 26, 2026, Enlivex's RAIN token holdings were 79,568,550,005 tokens, with a total value of approximately $919 million.
In addition, Enlivex holds an option to acquire up to 271,372,418,179 RAIN tokens from the Rain Foundation, at a purchase price of $0.0033 per RAIN token. The option’s

Enlivex Treasury Portfolio Update: Rain Protocol Jumps Into Top Three Global Prediction Markets In League Table Following $100M In Additional Liquidity

Wed, 27 May 2026 08:00:00 -0400

Rain, with an additional $100 Million Liquidity Commitment, Currently Anchors Top Three Positioning Among Global Prediction Market Leaders, Following Polymarket, with Approximately $450 million, and Kalshi1.
Rain’s Upgraded Positioning as a Top-3 Prediction Market and the Scale of its Capital Deployment Reinforce the Potential of the Enlivex Treasury Strategy
As of May 26, 2026, Enlivex's RAIN token holdings were 79,568,550,005 tokens, with a total value of approximately $919 million.
In addition, Enlivex holds an option to acquire up to 271,372,418,179 RAIN tokens from the Rain Foundation, at a purchase price of $0.0033 per RAIN token. The option’s

Enlivex Treasury Portfolio Update: Rain Protocol Jumps Into Top Three Global Prediction Markets In League Table Following $100M In Additional Liquidity

Wed, 27 May 2026 08:00:00 -0400

Rain, with an additional $100 Million Liquidity Commitment, Currently Anchors Top Three Positioning Among Global Prediction Market Leaders, Following Polymarket, with Approximately $450 million, and Kalshi1.
Rain’s Upgraded Positioning as a Top-3 Prediction Market and the Scale of its Capital Deployment Reinforce the Potential of the Enlivex Treasury Strategy
As of May 26, 2026, Enlivex's RAIN token holdings were 79,568,550,005 tokens, with a total value of approximately $919 million.
In addition, Enlivex holds an option to acquire up to 271,372,418,179 RAIN tokens from the Rain Foundation, at a purchase price of $0.0033 per RAIN token. The option’s

Enlivex Treasury Portfolio Update: Rain Protocol Jumps Into Top Three Global Prediction Markets In League Table Following $100M In Additional Liquidity

Wed, 27 May 2026 08:00:00 -0400

Rain, with an additional $100 Million Liquidity Commitment, Currently Anchors Top Three Positioning Among Global Prediction Market Leaders, Following Polymarket, with Approximately $450 million, and Kalshi1.
Rain’s Upgraded Positioning as a Top-3 Prediction Market and the Scale of its Capital Deployment Reinforce the Potential of the Enlivex Treasury Strategy
As of May 26, 2026, Enlivex's RAIN token holdings were 79,568,550,005 tokens, with a total value of approximately $919 million.
In addition, Enlivex holds an option to acquire up to 271,372,418,179 RAIN tokens from the Rain Foundation, at a purchase price of $0.0033 per RAIN token. The option’s

Enlivex Treasury Portfolio Update: Rain Protocol Jumps Into Top Three Global Prediction Markets In League Table Following $100M In Additional Liquidity

Wed, 27 May 2026 08:00:00 -0400

Rain, with an additional $100 Million Liquidity Commitment, Currently Anchors Top Three Positioning Among Global Prediction Market Leaders, Following Polymarket, with Approximately $450 million, and Kalshi1.
Rain’s Upgraded Positioning as a Top-3 Prediction Market and the Scale of its Capital Deployment Reinforce the Potential of the Enlivex Treasury Strategy
As of May 26, 2026, Enlivex's RAIN token holdings were 79,568,550,005 tokens, with a total value of approximately $919 million.
In addition, Enlivex holds an option to acquire up to 271,372,418,179 RAIN tokens from the Rain Foundation, at a purchase price of $0.0033 per RAIN token. The option’s

Enlivex Treasury Portfolio Update: Rain Protocol Jumps Into Top Three Global Prediction Markets In League Table Following $100M In Additional Liquidity

Wed, 27 May 2026 08:00:00 -0400

Rain, with an additional $100 Million Liquidity Commitment, Currently Anchors Top Three Positioning Among Global Prediction Market Leaders, Following Polymarket, with Approximately $450 million, and Kalshi1.
Rain’s Upgraded Positioning as a Top-3 Prediction Market and the Scale of its Capital Deployment Reinforce the Potential of the Enlivex Treasury Strategy
As of May 26, 2026, Enlivex's RAIN token holdings were 79,568,550,005 tokens, with a total value of approximately $919 million.
In addition, Enlivex holds an option to acquire up to 271,372,418,179 RAIN tokens from the Rain Foundation, at a purchase price of $0.0033 per RAIN token. The option’s

Enlivex Treasury Portfolio Update: Rain Protocol Jumps Into Top Three Global Prediction Markets In League Table Following $100M In Additional Liquidity

Wed, 27 May 2026 08:00:00 -0400

Rain, with an additional $100 Million Liquidity Commitment, Currently Anchors Top Three Positioning Among Global Prediction Market Leaders, Following Polymarket, with Approximately $450 million, and Kalshi1.
Rain’s Upgraded Positioning as a Top-3 Prediction Market and the Scale of its Capital Deployment Reinforce the Potential of the Enlivex Treasury Strategy
As of May 26, 2026, Enlivex's RAIN token holdings were 79,568,550,005 tokens, with a total value of approximately $919 million.
In addition, Enlivex holds an option to acquire up to 271,372,418,179 RAIN tokens from the Rain Foundation, at a purchase price of $0.0033 per RAIN token. The option’s

Form 6-K Enlivex Ltd. For: May 18

Mon, 18 May 2026 08:02:00 -0400
si-local-file:///var/storage/secattach/20260518/26510541.html

Form 6-K Enlivex Ltd. For: May 18

Mon, 18 May 2026 08:02:00 -0400
si-local-file:///var/storage/secattach/20260518/26510541.html

Enlivex doses first US patient in phase 2b knee osteoarthritis trial

Mon, 18 May 2026 08:01:37 -0400

Enlivex Ltd. (NASDAQ: ENLV) announced it has dosed the first patient at a United States clinical site in its Phase 2b trial of Allocetra for treating moderate-to-severe age-related primary knee osteoarthritis.

The dosing follows regulatory approvals received earlier this year, including FDA IND clearance in March and Danish Medicines Agency approval in April. The global, multicenter, randomized, double-blind, placebo-controlled trial is enrolling patients from clinical centers in the United States, Denmark and Poland.

The study evaluates the efficacy and safety of intra-articular injections of Allocetra in patients with moderate-to-severe age-related symptomatic primary knee osteoarthritis. Key efficacy endpoints include changes from baseline of

Enlivex doses first US patient in phase 2b knee osteoarthritis trial

Mon, 18 May 2026 08:01:37 -0400

Enlivex Ltd. (NASDAQ: ENLV) announced it has dosed the first patient at a United States clinical site in its Phase 2b trial of Allocetra for treating moderate-to-severe age-related primary knee osteoarthritis.

The dosing follows regulatory approvals received earlier this year, including FDA IND clearance in March and Danish Medicines Agency approval in April. The global, multicenter, randomized, double-blind, placebo-controlled trial is enrolling patients from clinical centers in the United States, Denmark and Poland.

The study evaluates the efficacy and safety of intra-articular injections of Allocetra in patients with moderate-to-severe age-related symptomatic primary knee osteoarthritis. Key efficacy endpoints include changes from baseline of